•Big Pharma is no longer interested in the manufacture and promotion of niche drugs such as those used in the treatment of rare and orphan diseases.
•Several essential drugs have already been withdrawn from the market.
•Leaving physicians and patients desperately waiting for vital treatments.
The reasons for discontinuation of these products includes: lower sales and disproportionately high costs for maintaining required regulatory and pharmacovigilance activities, high supply chain costs and decreasing contributions to profits.
•HEXIM PHARMACEUTICALS is a global Niche and Specialty pharmaceutical company, with Corporate Headquarters in New Jersey and subsidiaries in the EU, Asia and the Middle East.
HEXIM PHARMACEUTICALS offers integrated marketing, distribution and logistics operations and holds more than 40 drug molecules in its portfolio
Areas of expertise: Oncology, Supportive Care, Dermatology, Emergency Care and Rare Diseases.